Plerixafor: What we still have to learn

Francesco Lanza, Angelo Gardellini, Daniele Laszlo, Massimo Martino

Research output: Contribution to journalArticle


Plerixafor, a hematopoietic stem cell mobilizer, is indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. Current evidence suggests that the addition of plerixafor with chemotherapy plus G-CSF is safe and effective in the large majority of the patients with low blood CD34+ cell count after mobilization and/or poor yield after the first collection. Nevertheless, there are several questions strongly debated, and in this paper, we would like to identify areas of possible future use and development of the drug.

Original languageEnglish
Pages (from-to)143-147
Number of pages5
JournalExpert Opinion on Biological Therapy
Issue number2
Publication statusPublished - Feb 1 2015


  • Autologous transplantation
  • Mobilization
  • Peripheral blood stem cells
  • Plerixafor

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery
  • Medicine(all)

Fingerprint Dive into the research topics of 'Plerixafor: What we still have to learn'. Together they form a unique fingerprint.

  • Cite this